Korea Research Institute of Bioscience and Biotechnology (KRIBB) will embark on the development of a digital preclinical platform.
KRIBB noted that it hosted the '2025 AI Digital Bio Symposium' at its Daejeon headquarters on the 12th. At this forum, a prototype of the 'web-based pharmacokinetic evaluation platform,' the first step in developing AI digital bio new drugs, was unveiled.
AI-based drug development platforms are actively being developed around the world. In South Korea, the Ministry of Science and ICT and the Ministry of Health and Welfare are promoting the 'Collaborative Learning Drug Development Acceleration Project.' KRIBB is also participating in this initiative through the National Preclinical Research Center.
The National Preclinical Research Center plans to establish a digital preclinical platform that purposefully verifies efficacy with ultra-speed, high efficiency, and high quality, predicting preclinical results. This platform is a system that models and simulates preclinical data in real time, providing comprehensive predictions and support for the entire cycle of new drug development.
Nam Hyuk-mo, head of the Advanced Biotechnology Division at the Ministry of Science and ICT, said, "As the transition to leading drug development research in AI digital bio is crucial at this time, we expect rapid and efficient drug development through the establishment of the digital preclinical platform."
Go Kyung-cheol, head of the National Preclinical Research Center, remarked, "The digital preclinical platform will become a key to addressing national challenges by expanding to various targets, including unknown infectious diseases (Disease X) and rare diseases in the future," adding that they intend to enhance competitiveness in AI digital bio drug development and strengthen sovereignty capabilities in vaccine and treatment development.